We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Read MoreHide Full Article
Key Takeaways
INCY's Q3 revenues are expected to benefit from Jakafi sales, with the consensus estimate at $827M.
Opzelura sales are estimated at $230M, supported by patient starts, refills and a CMS settlement.
Niktimvo and other marketed drugs may boost revenues, while higher R&D and SG&A costs could raise expenses.
Incyte Corporation (INCY - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.48 billion, while the same for the bottom line is pinned at a loss of $3.50 per share.
Let us look at how things are likely to have shaped up for INCY in the to-be-reported quarter.
Factors Likely to Influence INCY's Q3 Results
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have continued on the back of strong Jakafi sales, a first-in-class, selective JAK1/JAK2 inhibitor, across all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]).
The Zacks Consensus Estimate for Jakafi's third-quarter sales is pegged at $827 million.
Incyte also earns product royalty revenues from Novartis (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets.
While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter due to potentially higher Jakavi sales.
Year to date, Incyte shares have gained 18.4% compared with the industry’s 6.7% growth.
Image Source: Zacks Investment Research
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
In the to-be-reported quarter, Opzelura (ruxolitinib cream) sales are expected to have been driven by continued growth in patient starts and refills in the United States for its two approved indications: atopic dermatitis and vitiligo. The European Union (EU) approval of Opzelura for moderate atopic dermatitis is expected to support Incyte’s sales growth in the coming quarters by expanding the drug’s addressable market beyond its existing European vitiligo indication.
The CMS settlement is expected to support Opzelura’s net sales in the second half of 2026, with Incyte estimating a combined $40-$50 million benefit in the third and fourth quarters from improved gross-to-net performance.
The Zacks Consensus Estimate for Opzelura’s third-quarter sales is pegged at $230 million.
While Jakafi’s sales and royalties are the key catalysts for Incyte’s revenue growth, sales of other drugs like Minjuvi, Pemazyre and Iclusig, and Olumiant’s royalties from Eli Lilly (LLY - Free Report) are also likely to have contributed to Incyte’s top line. INCY has a collaboration agreement with LLY for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Incyte acquired exclusive global rights to Monjuvi/Minjuvi (tafasitamab), initially approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma, from MorphoSys in 2024. Last year, the FDA approved Monjuvi for relapsed or refractory follicular lymphoma, expanding its label and boosting sales. Minjuvi also secured approvals for this indication in the EU and Japan in 2025.
The Zacks Consensus Estimate for Iclusig, Minjuvi/Monjuvi and Pemazyre’s third-quarter sales is pegged at $35.2 million, $55 million and $23.5 million, respectively. Incremental sales from Zynyz are also expected to have contributed to Incyte’s revenues in the to-be-reported quarter.
Incyte and partner Syndax launched Niktimvo (axatilimab-csfr) in the United States in early 2025 after FDA approval for chronic graft-versus-host disease (cGvHD) patients who have failed at least two prior systemic therapies. Niktimvo is Incyte's second approved treatment for cGvHD (third-line). The Zacks Consensus Estimate for Niktimvo’s third-quarter sales is pegged at $64 million.
Incyte granted Mirum Pharmaceuticals worldwide rights to Atebrioz (zilurgisertib) in April 2026. Following its FDA approval for fibrodysplasia ossificans progressiva, the drug is expected to launch this month. Incyte is eligible for milestone payments and royalties on global sales. Investors will look for updates on the launch and potential revenue contribution during the upcoming earnings call.
Higher research and development (R&D) expenses, as well as increased selling, general and administrative (SG&A) costs, are likely to have escalated operating expenses in the third quarter of 2026.
Incyte has a mixed history of earnings surprises. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 28.65%. In the last reported quarter, INCY posted an earnings surprise of 54.50%.
Earnings Whispers for INCY
Our proven model does not conclusively predict an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Earnings ESP: Incyte’s Earnings ESP is -11.02% as the Most Accurate Estimate stands at a loss of $3.89, higher than the Zacks Consensus Estimate for a loss of $3.50. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Zacks Rank: INCY has a Zacks Rank #4 (Sell) at present.
Stock to Consider
Here is a stock worth considering from the healthcare space, as our model shows that this has the right combination of elements to beat on earnings this reporting cycle.
HALO shares have gained 85.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering a negative average surprise of 19.12%. Halozyme is scheduled to report third-quarter results on Nov. 5.
View the Zacks #1 Rank List
Image: Bigstock
Incyte Gears Up to Report Q3 Earnings: Will Results Disappoint?
Key Takeaways
Incyte Corporation (INCY - Free Report) is scheduled to report third-quarter 2026 earnings on Oct. 29, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $1.48 billion, while the same for the bottom line is pinned at a loss of $3.50 per share.
Let us look at how things are likely to have shaped up for INCY in the to-be-reported quarter.
Factors Likely to Influence INCY's Q3 Results
Incyte primarily derives product revenues from the sales of its lead drug, Jakafi (ruxolitinib), in the United States, as well as from the sales of other marketed drugs. Its momentum is likely to have continued on the back of strong Jakafi sales, a first-in-class, selective JAK1/JAK2 inhibitor, across all approved indications (polycythemia vera, myelofibrosis and refractory acute graft-versus-host disease [GvHD]).
The Zacks Consensus Estimate for Jakafi's third-quarter sales is pegged at $827 million.
Incyte also earns product royalty revenues from Novartis (NVS - Free Report) for the commercialization of Jakafi in ex-U.S. markets.
While Incyte markets Jakafi in the United States, Novartis markets the same drug as Jakavi outside the United States. INCY is expected to have received higher royalties from NVS in the to-be-reported quarter due to potentially higher Jakavi sales.
Year to date, Incyte shares have gained 18.4% compared with the industry’s 6.7% growth.
Image Source: Zacks Investment Research
Incyte also receives royalties from the sales of Tabrecta (capmatinib), which is approved for treating adult patients with metastatic non-small cell lung cancer. Novartis has exclusive worldwide development and commercialization rights to Tabrecta.
In the to-be-reported quarter, Opzelura (ruxolitinib cream) sales are expected to have been driven by continued growth in patient starts and refills in the United States for its two approved indications: atopic dermatitis and vitiligo. The European Union (EU) approval of Opzelura for moderate atopic dermatitis is expected to support Incyte’s sales growth in the coming quarters by expanding the drug’s addressable market beyond its existing European vitiligo indication.
The CMS settlement is expected to support Opzelura’s net sales in the second half of 2026, with Incyte estimating a combined $40-$50 million benefit in the third and fourth quarters from improved gross-to-net performance.
The Zacks Consensus Estimate for Opzelura’s third-quarter sales is pegged at $230 million.
While Jakafi’s sales and royalties are the key catalysts for Incyte’s revenue growth, sales of other drugs like Minjuvi, Pemazyre and Iclusig, and Olumiant’s royalties from Eli Lilly (LLY - Free Report) are also likely to have contributed to Incyte’s top line. INCY has a collaboration agreement with LLY for Olumiant. The drug is a once-daily oral JAK inhibitor discovered by Incyte and licensed to LLY. It is approved for several types of autoimmune diseases.
Incyte acquired exclusive global rights to Monjuvi/Minjuvi (tafasitamab), initially approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma, from MorphoSys in 2024. Last year, the FDA approved Monjuvi for relapsed or refractory follicular lymphoma, expanding its label and boosting sales. Minjuvi also secured approvals for this indication in the EU and Japan in 2025.
The Zacks Consensus Estimate for Iclusig, Minjuvi/Monjuvi and Pemazyre’s third-quarter sales is pegged at $35.2 million, $55 million and $23.5 million, respectively. Incremental sales from Zynyz are also expected to have contributed to Incyte’s revenues in the to-be-reported quarter.
Incyte and partner Syndax launched Niktimvo (axatilimab-csfr) in the United States in early 2025 after FDA approval for chronic graft-versus-host disease (cGvHD) patients who have failed at least two prior systemic therapies. Niktimvo is Incyte's second approved treatment for cGvHD (third-line). The Zacks Consensus Estimate for Niktimvo’s third-quarter sales is pegged at $64 million.
Incyte granted Mirum Pharmaceuticals worldwide rights to Atebrioz (zilurgisertib) in April 2026. Following its FDA approval for fibrodysplasia ossificans progressiva, the drug is expected to launch this month. Incyte is eligible for milestone payments and royalties on global sales. Investors will look for updates on the launch and potential revenue contribution during the upcoming earnings call.
Higher research and development (R&D) expenses, as well as increased selling, general and administrative (SG&A) costs, are likely to have escalated operating expenses in the third quarter of 2026.
Incyte Corporation Price and Consensus
Incyte Corporation price-consensus-chart | Incyte Corporation Quote
INCY's Earnings Surprise History
Incyte has a mixed history of earnings surprises. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 28.65%. In the last reported quarter, INCY posted an earnings surprise of 54.50%.
Earnings Whispers for INCY
Our proven model does not conclusively predict an earnings beat for INCY this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Earnings ESP: Incyte’s Earnings ESP is -11.02% as the Most Accurate Estimate stands at a loss of $3.89, higher than the Zacks Consensus Estimate for a loss of $3.50. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
INCY’s Zacks Rank: INCY has a Zacks Rank #4 (Sell) at present.
Stock to Consider
Here is a stock worth considering from the healthcare space, as our model shows that this has the right combination of elements to beat on earnings this reporting cycle.
Halozyme Therapeutics (HALO - Free Report) has an Earnings ESP of +2.78% and currently flaunts a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
HALO shares have gained 85.1% year to date. The company’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, delivering a negative average surprise of 19.12%. Halozyme is scheduled to report third-quarter results on Nov. 5.